Amarin

Amarin raises $200M ahead of Vascepa push
Amarin raises $200M ahead of Vascepa push
BioCentury
Amarin
Vascepa
Flag link:
Amarin's Vascepa trial stirs data debate as stock drops 10%
Amarin's Vascepa trial stirs data debate as stock drops 10%
Biopharma Dive
Amarin
Vascepa
Flag link:
Amarin's Fish-Oil-Derived Drug Shows Great Promise — With Big Caveats
Amarin's Fish-Oil-Derived Drug Shows Great Promise — With Big Caveats
Forbes
Amarin
Vascepa
Flag link:
Why Amarin Stock Jumped 28% in October -- and Why a Bigger Move Could Come Soon
Why Amarin Stock Jumped 28% in October -- and Why a Bigger Move Could Come Soon
Motley Fool
Amarin
Vascepa
Flag link:
Experts question Amarin's early touting of Vescepa data ahead of detailed results
Experts question Amarin's early touting of Vescepa data ahead of detailed results
Endpoints
Amarin
Vascepa
heart disease
Flag link:
[video+transcript] How Big Could Amarin's Vascepa Be?
[video+transcript] How Big Could Amarin's Vascepa Be?
Motley Fool
Vascepa
Amarin
Flag link:
3 Drugmakers Not Pleased With Amarin's Fish Oil Triumph
3 Drugmakers Not Pleased With Amarin's Fish Oil Triumph
Yahoo/Motley Fool
Amarin
Vascepa
Amgen
Sanofi
Regeneron
Flag link:
Amarin Soars as Fish Oil Pill Cuts Risk of Strokes in Long-Awaited Study
Amarin Soars as Fish Oil Pill Cuts Risk of Strokes in Long-Awaited Study
Xconomy
Amarin
fish oil
strokes
Vascepa
Flag link:
Why Amarin Corporation Skyrocketed 23.9% in August
Why Amarin Corporation Skyrocketed 23.9% in August
Motley Fool
Amarin
Vascepa
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings
Yahoo/Benzinga
Adamis
GSK
Sangamo BioSciences
Roche
Bluebird Bio
ProQR Therapeutics
Geron
Amarin
Palatin
EyeGate
Galactin
Omeros
Atossa Genetics
Flag link:
Amarin Corporation, CRISPR Therapeutics, and Geron Corporation could all see big gains next week
Amarin Corporation, CRISPR Therapeutics, and Geron Corporation could all see big gains next week
Motley Fool
Amarin
CRISPR Therapeutics
Geron
Vascepa
Vertex Pharmaceuticals
CTX001
JNJ
imetelstat
Flag link:
Analysts: Amarin poised for huge gains if Vascepa trial comes back positive
Analysts: Amarin poised for huge gains if Vascepa trial comes back positive
Medical Marketing and Media
Amarin
Vascepa
Flag link:
Amarin's Vascepa goes on TV to lay groundwork for impending CV outcomes data
Amarin's Vascepa goes on TV to lay groundwork for impending CV outcomes data
Fierce Pharma
Amarin
Vascepa
physicians
television ads
Flag link:
Sink or swim for fish oils, and Amarin
Sink or swim for fish oils, and Amarin
EP Vantage
Amarin
Vascepa
Flag link:
Boom-or-Bust News Is On Tap Soon for Amarin
Boom-or-Bust News Is On Tap Soon for Amarin
Motley Fool
Amarin
Vascepa
triglycerides
Flag link:
Amarin's Salyer preps for Vascepa push
Amarin's Salyer preps for Vascepa push
Medical Marketing and Media
Amarin
Vascepa
Flag link:
8 Major FDA Decisions and Trial Results to Watch for in September
8 Major FDA Decisions and Trial Results to Watch for in September
24/7 Wall St
FDA
Achillion
odalasvir
AL-335
simeprevir
Amarin
Vascepa
Array Biopharma
binimetinib
Mast Therapeutics
vepoloxamer
Novavax
Threshold Pharmaceuticals
tarloxotinib
Flag link:
Amarin slips after adding second interim efficacy trial to PhIII CV trial
Amarin slips after adding second interim efficacy trial to PhIII CV trial
Fierce Biotech
Amarin
clinical trials
Vascepa
Flag link:
This Tiny Biopharma Has Been Bucking The Downtrend
This Tiny Biopharma Has Been Bucking The Downtrend
Motley Fool
Amarin
Vascepa
Flag link:
Amarin - Vascepa Gains Protection Until At Least 2020
Amarin - Vascepa Gains Protection Until At Least 2020
Seeking Alpha
Amarin
Vascepa
FDA
market exclusivity
Flag link:

Pages